Secondary Logo

Institutional members access full text with Ovid®

Pitfalls to avoid when treating patients with metastatic bone disease

Lerman, Daniel M.; Randall, R. Lor

doi: 10.1097/BCO.0000000000000172
SPECIAL FOCUS: Tumors
Buy

The surgical management of patients with impending or realized pathologic fractures is fraught with multiple potential pitfalls. Many of these are unique to patients with metastatic bone disease and therefore warrant additional attention. An ordered systemic preoperative evaluation helps to prevent diagnostic omissions. A whole body bone scan and subsequent radiographic evaluation of all active lesions allows the identification of additional sites of concern that were not apparent on presentation. Determination of the tissue of origin, which is typically made with a thorough diagnostic evaluation, has implications for perioperative management and projected patient longevity that may influence operative planning. Before surgical intervention a histologic confirmation of metastatic disease must be obtained to prevent incidental intervention for a nonmetastatic lesion. Lastly, serum calcium levels should be assessed to rule out malignancy-associated hypercalcemia, a potentially fatal complication with nonspecific symptoms and an indolent progression. Both skeletal disease burden and projected patient longevity may influence whether skeletal fixation or arthroplasty is performed. Regardless of which modality is employed, a few general principles are constant. Surgical intervention should provide a durable reconstruction that allows immediate weight bearing and whose success is independent of osseous healing, which is unlikely to occur. As standard practice, long-stem, full-length implants are used to prophylactically splint the uninvolved segments of the operated bone, protecting against further disease progression. Optimal postoperative management requires use of localized and systemic therapies to limit metastatic disease progression and improve patient outcomes.

Sarcoma Services, Department of Orthopaedics, Huntsman Cancer Institute, University of Utah and Primary Children’s Hospital, Salt Lake City, Utah

Financial Disclosure: Dr. Randall is a paid consultant for Biomet. The authors report no conflicts of interest.

Correspondence to R. Lor Randall, MD, FACS, Huntsman Cancer Institute, 2000 Circle of Hope, Room 4260, Salt Lake City, UT 84112 Tel: +801-585-1122; fax: +801-585-7084; e-mail: Lor.Randall@hci.utah.edu

© 2014 Wolters Kluwer Health | Lippincott Williams & Wilkins